Home › Endometrial Cancer › NCT07278986

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Imaging of Patients With Endometrial Cancer Planned for Surgery

Who can join

Ages 18 and older · Women

Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Adult subjects 18 years of age and older
3. Primary diagnosis of endometrial cancer
4. Scheduled to undergo surgery for endometrial cancer
5. Ability to understand the requirements of the study and agree to abide by the study restrictions and to return for the required assessments
6. Willingness to stop the use of folate or folic acid supplements at least 48 hours prior to infusion of study drug

Exclusion Criteria:

1. Pregnancy or positive pregnancy test
2. Any medical condition that in the opinion of the investigator could potentially jeopardize the safety of the subject
3. History of anaphylactic reactions to products containing indocyanine green
4. History of allergy to any of the components of CYTALUX
5. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule

About the study

The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.

What is being tested

• CYTALUX™ (pafolacianine) (drug)
• 1788 4K Camera System with Advanced Imaging Modality (device)

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 10 · Started: Oct 18, 2025

Contact the study team

• Brianna Aguilar · Phone: 215-615-6770
• Joseph Agyemang · Phone: 215-490-4121

Official record on ClinicalTrials.gov — NCT07278986

Locations in the U.S.

Conditions

• Endometrial Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.